129 related articles for article (PubMed ID: 16456813)
21. An immunohistochemical study of p53 protein in cervical intraepithelial neoplasia and squamous cell carcinoma.
Raju GC; Teh M; Wee A
Pathology; 1996 Jan; 28(1):17-19. PubMed ID: 8714263
[TBL] [Abstract][Full Text] [Related]
22. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma.
Xu LN; Zou SQ; Wang JM
World J Gastroenterol; 2005 Jun; 11(24):3719-23. PubMed ID: 15968727
[TBL] [Abstract][Full Text] [Related]
23. [Expression of angiotensin II type 1 receptor in cervical squamous cell carcinoma and its clinical significance].
Liao YD; Xu H; Han Q; Lei J; Zhang YY; Wang ZH
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):360-4. PubMed ID: 17892132
[TBL] [Abstract][Full Text] [Related]
24. Suppression of FasL expression in tumor cells and preventing tumor necrosis factor-induced apoptosis by adenovirus 14.7K is an effective escape mechanism for immune cells.
Zhang J; Xu G
Cancer Genet Cytogenet; 2007 Dec; 179(2):112-7. PubMed ID: 18036397
[TBL] [Abstract][Full Text] [Related]
25. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes.
Kim JW; Wieckowski E; Taylor DD; Reichert TE; Watkins S; Whiteside TL
Clin Cancer Res; 2005 Feb; 11(3):1010-20. PubMed ID: 15709166
[TBL] [Abstract][Full Text] [Related]
26. Characterization and functional analysis of the expression of vascular adhesion molecules in human papillomavirus-related disease of the cervix.
Coleman N; Stanley MA
Cancer; 1994 Aug; 74(3):884-92. PubMed ID: 7518736
[TBL] [Abstract][Full Text] [Related]
27. Fas (APO-1/CD95) ligand and Fas expression in renal cell carcinomas: correlation with the prognostic factors.
Kim YS; Kim KH; Choi JA; Lee JH; Kim HK; Won NH; Kim I
Arch Pathol Lab Med; 2000 May; 124(5):687-93. PubMed ID: 10782148
[TBL] [Abstract][Full Text] [Related]
28. Irradiation-induced up-regulation of Fas in esophageal squamous cell carcinoma is not accompanied by Fas ligand-mediated apoptosis.
Rigberg DA; Centeno J; Kim FS; Ke B; Swenson K; Maggard M; McFadden DW
J Surg Oncol; 1999 Jun; 71(2):91-6. PubMed ID: 10389864
[TBL] [Abstract][Full Text] [Related]
29. Correlation of E6 and E7 levels in high-risk HPV16 type cervical lesions with CCL20 and Langerhans cells.
Jiang B; Xue M
Genet Mol Res; 2015 Sep; 14(3):10473-81. PubMed ID: 26400278
[TBL] [Abstract][Full Text] [Related]
30. Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression.
Acs G; Zhang PJ; McGrath CM; Acs P; McBroom J; Mohyeldin A; Liu S; Lu H; Verma A
Am J Pathol; 2003 Jun; 162(6):1789-806. PubMed ID: 12759237
[TBL] [Abstract][Full Text] [Related]
31. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.
Mitsiades N; Poulaki V; Mastorakos G; Tseleni-Balafouta ST; Kotoula V; Koutras DA; Tsokos M
J Clin Endocrinol Metab; 1999 Aug; 84(8):2924-32. PubMed ID: 10443700
[TBL] [Abstract][Full Text] [Related]
32. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic cancer cells can evade immune surveillance via nonfunctional Fas (APO-1/CD95) receptors and aberrant expression of functional Fas ligand.
von Bernstorff W; Spanjaard RA; Chan AK; Lockhart DC; Sadanaga N; Wood I; Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1999 Jan; 125(1):73-84. PubMed ID: 9889801
[TBL] [Abstract][Full Text] [Related]
34. Alterations in the expression of selected MHC antigens in premalignant lesions and squamous carcinomas of the uterine cervix.
Chil A; Sikorski M; Bobek M; Jakiel G; Marcinkiewicz J
Acta Obstet Gynecol Scand; 2003 Dec; 82(12):1146-52. PubMed ID: 14616262
[TBL] [Abstract][Full Text] [Related]
35. Overexpression of heat shock protein 27 in squamous cell carcinoma of the uterine cervix: a proteomic analysis using archival formalin-fixed, paraffin-embedded tissues.
Ono A; Kumai T; Koizumi H; Nishikawa H; Kobayashi S; Tadokoro M
Hum Pathol; 2009 Jan; 40(1):41-9. PubMed ID: 18755499
[TBL] [Abstract][Full Text] [Related]
36. Frequent HLA class I loss is an early event in cervical carcinogenesis.
Vermeulen CF; Jordanova ES; Zomerdijk-Nooijen YA; ter Haar NT; Peters AA; Fleuren GJ
Hum Immunol; 2005 Nov; 66(11):1167-73. PubMed ID: 16571417
[TBL] [Abstract][Full Text] [Related]
37. Tumor necrosis factor-alpha and interferon-gamma induce expression of functional Fas ligand on HT29 and MCF7 adenocarcinoma cells.
Naujokat C; Sezer O; Possinger K
Biochem Biophys Res Commun; 1999 Nov; 264(3):813-9. PubMed ID: 10544014
[TBL] [Abstract][Full Text] [Related]
38. Indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase expression in HPV infection, SILs, and cervical cancer.
Venancio PA; Consolaro MEL; Derchain SF; Boccardo E; Villa LL; Maria-Engler SS; Campa A; Discacciati MG
Cancer Cytopathol; 2019 Sep; 127(9):586-597. PubMed ID: 31412167
[TBL] [Abstract][Full Text] [Related]
39. Addressing the "Fas counterattack" controversy: blocking fas ligand expression suppresses tumor immune evasion of colon cancer in vivo.
Ryan AE; Shanahan F; O'Connell J; Houston AM
Cancer Res; 2005 Nov; 65(21):9817-23. PubMed ID: 16267003
[TBL] [Abstract][Full Text] [Related]
40. Suppression of FasL expression in tumor cells and preventing TNF-induced apoptosis was better for immune cells survival.
Xu G; Zhang J
J Cancer Res Clin Oncol; 2008 Oct; 134(10):1043-9. PubMed ID: 18461366
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
